ArriVent BioPharma, Inc. AVBP
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
ArriVent BioPharma, Inc. (AVBP) is a healthcare company listed in the US with a market value of about $673M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -37%.
About ArriVent BioPharma
ArriVent BioPharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | -$166M | -$80M | -$69M |
| Free cash flow | — | — | — |
| EPS (diluted) | $-4.32 | $-2.56 | $-32.38 |
| Net margin | — | — | — |
| ROIC | -45.6% | -28.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $26.40, 103% above the current price; targets range from $22.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-3.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does ArriVent BioPharma pay a dividend?
Not currently.
Is ArriVent BioPharma a good stock to buy?
We do not give buy or sell advice. ArriVent BioPharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.